Cargando…

Current management options for recurrent adrenocortical carcinoma

Adrenal cortical carcinoma (ACC) is a rare cancer that poses a number of management challenges due to the limited number of effective systemic treatments. Complete surgical resection offers the best chance of long-term survival. However, despite complete resection, ACC is associated with high recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Glover, Anthony R, Ip, Julian C Y, Zhao, Jing Ting, Soon, Patsy S H, Robinson, Bruce G, Sidhu, Stan B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681406/
https://www.ncbi.nlm.nih.gov/pubmed/23776337
http://dx.doi.org/10.2147/OTT.S34956
_version_ 1782273261277544448
author Glover, Anthony R
Ip, Julian C Y
Zhao, Jing Ting
Soon, Patsy S H
Robinson, Bruce G
Sidhu, Stan B
author_facet Glover, Anthony R
Ip, Julian C Y
Zhao, Jing Ting
Soon, Patsy S H
Robinson, Bruce G
Sidhu, Stan B
author_sort Glover, Anthony R
collection PubMed
description Adrenal cortical carcinoma (ACC) is a rare cancer that poses a number of management challenges due to the limited number of effective systemic treatments. Complete surgical resection offers the best chance of long-term survival. However, despite complete resection, ACC is associated with high recurrence rates. This review will discuss the management of recurrent ACC in adults following complete surgical resection. Management should take place in a specialist center and treatment decisions must consider the individual tumor biology of each case of recurrence. Given the fact that ACC commonly recurs, management to prevent recurrence should be considered from initial diagnosis with the use of adjuvant mitotane. Close follow up with clinical examination and imaging is important for early detection of recurrent disease. Locoregional recurrence may be isolated, and repeat surgical resection should be considered along with mitotane. The use of radiotherapy in ACC remains controversial. Systemic recurrence most often involves liver, pulmonary, and bone metastasis and is usually managed with mitotane, with or without combination chemotherapy. There is a limited role for surgical resection in systemic recurrence in selected patients. In all patients with recurrent disease, control of excessive hormone production is an important part of management. Despite intensive management of recurrent ACC, treatment failure is common and the use of clinical trials and novel treatment is an important part of management.
format Online
Article
Text
id pubmed-3681406
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36814062013-06-17 Current management options for recurrent adrenocortical carcinoma Glover, Anthony R Ip, Julian C Y Zhao, Jing Ting Soon, Patsy S H Robinson, Bruce G Sidhu, Stan B Onco Targets Ther Review Adrenal cortical carcinoma (ACC) is a rare cancer that poses a number of management challenges due to the limited number of effective systemic treatments. Complete surgical resection offers the best chance of long-term survival. However, despite complete resection, ACC is associated with high recurrence rates. This review will discuss the management of recurrent ACC in adults following complete surgical resection. Management should take place in a specialist center and treatment decisions must consider the individual tumor biology of each case of recurrence. Given the fact that ACC commonly recurs, management to prevent recurrence should be considered from initial diagnosis with the use of adjuvant mitotane. Close follow up with clinical examination and imaging is important for early detection of recurrent disease. Locoregional recurrence may be isolated, and repeat surgical resection should be considered along with mitotane. The use of radiotherapy in ACC remains controversial. Systemic recurrence most often involves liver, pulmonary, and bone metastasis and is usually managed with mitotane, with or without combination chemotherapy. There is a limited role for surgical resection in systemic recurrence in selected patients. In all patients with recurrent disease, control of excessive hormone production is an important part of management. Despite intensive management of recurrent ACC, treatment failure is common and the use of clinical trials and novel treatment is an important part of management. Dove Medical Press 2013-06-06 /pmc/articles/PMC3681406/ /pubmed/23776337 http://dx.doi.org/10.2147/OTT.S34956 Text en © 2013 Glover et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Glover, Anthony R
Ip, Julian C Y
Zhao, Jing Ting
Soon, Patsy S H
Robinson, Bruce G
Sidhu, Stan B
Current management options for recurrent adrenocortical carcinoma
title Current management options for recurrent adrenocortical carcinoma
title_full Current management options for recurrent adrenocortical carcinoma
title_fullStr Current management options for recurrent adrenocortical carcinoma
title_full_unstemmed Current management options for recurrent adrenocortical carcinoma
title_short Current management options for recurrent adrenocortical carcinoma
title_sort current management options for recurrent adrenocortical carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681406/
https://www.ncbi.nlm.nih.gov/pubmed/23776337
http://dx.doi.org/10.2147/OTT.S34956
work_keys_str_mv AT gloveranthonyr currentmanagementoptionsforrecurrentadrenocorticalcarcinoma
AT ipjuliancy currentmanagementoptionsforrecurrentadrenocorticalcarcinoma
AT zhaojingting currentmanagementoptionsforrecurrentadrenocorticalcarcinoma
AT soonpatsysh currentmanagementoptionsforrecurrentadrenocorticalcarcinoma
AT robinsonbruceg currentmanagementoptionsforrecurrentadrenocorticalcarcinoma
AT sidhustanb currentmanagementoptionsforrecurrentadrenocorticalcarcinoma